High-Intensity Aerobic Interval Training in Testicular Cancer Survivors

Not Applicable

Completed

• Conditions: Testicular Neoplasms; Cardiovascular Diseases

• Registration Number: NCT02459132
• Lead Sponsor: University of Alberta

Brief Summary

This study evaluates the impact of a supervised 12-week high-intensity aerobic interval exercise program (versus a self-directed exercise usual care group) on traditional and novel cardiovascular disease risk factors and surrogate markers of cardiovascular- and overall-mortality in a population-based sample of testicular cancer survivors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-05-21
• Study First Submitted QC: 2015-05-29
• Study First Posted: 2015-06-01
• Study Start: 2015-07
• Status Verified: 2016-09
• Primary Completion: 2016-09
• Study Completion: 2017-04
• Last Update Submitted: 2017-04-20
• Last Update Posted: 2017-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 63

Inclusion Criteria

• histologically confirmed history of testicular cancer

Exclusion Criteria

• Not sufficiently ambulatory to complete the first two stages of the aerobic exercise test.
• Have a psychiatric condition which impairs their ability to perform the required volume and intensity of exercise.
• Have any uncontrolled cardiovascular condition (i.e. heart disease, hypertension, diabetes, arrhythmia).
• Report performing any weekly vigorous intensity aerobic exercise in the past month.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Peak aerobic capacity (relative VO2peak)	Baseline and within 7 days of completing the 12-week intervention	ml O2/kg/min

Secondary Outcome Measures

Name	Time	Method
Peak aerobic capacity (absolute VO2peak)	Baseline and within 7 days of completing the 12-week intervention	L/min
Postexercise 1-minute heart rate recovery	Baseline and within 7 days of completing the 12-week intervention	change in beats/min
Average carotid intima-media thickness	Baseline and within 7 days of completing the 12-week intervention	mm
Carotid distensibility	Baseline and within 7 days of completing the 12-week intervention	10-3/kPa
Velocity time integral	Baseline and within 7 days of completing the 12-week intervention	cm
Respiratory sinus arrhythmia	Baseline and within 7 days of completing the 12-week intervention	beats/min
Diastolic blood pressure	Baseline and within 7 days of completing the 12-week intervention	mmHg
Brachial diameter	Baseline and within 7 days of completing the 12-week intervention	mm
Maximal carotid intima-media thickness	Baseline and within 7 days of completing the 12-week intervention	mm
Carotid diameter	Baseline and within 7 days of completing the 12-week intervention	mm
Brachial flow-mediated dilation	Baseline and within 7 days of completing the 12-week intervention	percent dilation
Heart rate	Baseline and within 7 days of completing the 12-week intervention	beats/min
Systolic blood pressure	Baseline and within 7 days of completing the 12-week intervention	mmHg
Femoral-toe pulse wave velocity	Baseline and within 7 days of completing the 12-week intervention	m/s
Low-density lipoprotein	Baseline and within 7 days of completing the 12-week intervention	mmol/L
Total cholesterol : high-density lipoprotein ratio	Baseline and within 7 days of completing the 12-week intervention	ratio
Vascular age	Baseline and within 7 days of completing the 12-week intervention	years
Carotid-femoral pulse wave velocity	Baseline and within 7 days of completing the 12-week intervention	m/s
Fibrinogen	Baseline and within 7 days of completing the 12-week intervention	g/L
Total cholesterol	Baseline and within 7 days of completing the 12-week intervention	mmol/L
Shear stress during reactive hyperemia	Baseline and within 7 days of completing the 12-week intervention	dynes/cm2
High-density lipoprotein	Baseline and within 7 days of completing the 12-week intervention	mmol/L
Triglycerides	Baseline and within 7 days of completing the 12-week intervention	mmol/L
Testosterone	Baseline and within 7 days of completing the 12-week intervention	nmol/L
Framingham Risk Score	Baseline and within 7 days of completing the 12-week intervention	10 year CVD risk %
High-sensitivity C-reactive protein	Baseline and within 7 days of completing the 12-week intervention	mg/L
Fasting glucose	Baseline and within 7 days of completing the 12-week intervention	mmol/L
Modifiable CVD Risk Factor Score	Baseline and within 7 days of completing the 12-week intervention	Number (max 24)